Dr. Christopher Jones is a board-certified radiation oncologist who specializes in the use of ionizing radiation to treat cancer, focusing on tumors of the head and neck, prostate, and brain. He investigates optimal use of radiation therapy (radiotherapy) techniques including intensity modulated radiation therapy (IMRT), high-dose brachytherapy, and image-guided radiation therapy. Dr. Jones is a Principal Investigator for Radiation Therapy Oncology Group (RTOG) National Cancer Institute-sponsored oncology group clinical trials. He has authored numerous publications and abstracts on radiotherapy and imaging techniques to assess cancer progression, predict tumor recurrence after surgery and radiotherapy, and visualize response to treatment. Dr. Jones lectures nationally and internationally on the role of radiation therapy in the management of head and neck cancers.
Sutter Health Research Enterprise
2800 L Street, #10
Sacramento, CA, 95816
(916) 454-6600
simr@sutterhealth.org
Primary Research Interests
Related Clinical Trials
Adjuvant (ECOG-ACRIN EA3191)
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Ra
Investigator: Christopher Jones MD
Status: Active, Recruiting
Adjuvant (NRG BN003)
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Investigator: Christopher Jones MD
Status: Active, Recruiting
Adjuvant (RTOG 3506 STEEL)
A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide)
Investigators: Christopher Jones MD, Sivakumar Reddy M.D., Seth A Rosenthal Radiation Oncologist, David S Yee M.D., MPH
Status: Active, Recruiting
Adjuvant NRG HN001
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Investigator: Christopher Jones MD
Status: Active, Recruiting
First Line or Neoadjuvant (NRG-HN005)
De-intensified Radiation Therapy With Cisplatin or Nivolumab in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Investigator: Christopher Jones MD
Status: Active, Recruiting
Locally Advanced (NRG BN010) Temporarily on Hold
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
Investigator: Christopher Jones MD
Status: Active, Not Recruiting
Locally Advanced (NRG BN011)
Testing Addition of Chemo Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and RT) for Newly Diagnosed MGMT Methylated Glioblastoma
Investigator: Christopher Jones MD
Status: Active, Recruiting
Locally Advanced (NRG HN004) Temporarily on Hold
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Investigator: Christopher Jones MD
Status: Active, Not Recruiting
Locally Advanced (NRG HN009)
Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
Investigator: Christopher Jones MD
Status: Active, Recruiting
Locally Advanced (RTOG 1216)
Randomized Phase II/III Trial of Adjuvant Radiation Therapy (RT) with Cisplatin, Docetaxel Cetuximab, or Cisplatin Atezolizumab in Pathologic High Risk Squamous
Investigator: Christopher Jones MD
Status: Active, Recruiting
Metastatic (NRG-BN009)
Testing the Addition of HA-WBRT to SRS in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier SRS
Investigator: Christopher Jones MD
Status: Active, Recruiting
Neoadjuvant (COMPPARE)
A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE)
Investigator: Christopher Jones MD
Status: Active, Recruiting